Stephen Taub Premium Life Sciences Venture Investments Still Have a Pulse Several leading hedge funds specializing in life sciences and biopharma have been more active in the private markets this quarter. But overall volume is still way down from the highs. Stephen Taub March 24, 2022 Carsten Snejbjerg/Bloomberg